In previous studies we found that cholera toxin (CT) can act as a mucosal adjuvant; i.e., it can stimulate an intestinal secretory immunoglobulin A (S-IgA) response to an unrelated protein antigen when both are fed together to mice. The purpose of this study was to determine whether the mucosal adjuvanticity of CT is restricted by either H-2 major histocompatibility complex or lps genes by using congenic inbred strains that differ at only a single genetic locus. Groups of five mice each were fed saline, CT (10 ,ug), keyhole limpet hemocyanin (KLH) (5 mg), or both CT and KLH on four different days, and samples of intestinal secretions and plasma were obtained 1 week after the last feeding. In the mice fed both CT and KLH, the intestinal S-IgA anti-KLH response was higher in H-2e congenic strains than in H-2k congenic strains, and in addition there was a highly significant positive correlation between the intestinal S-IgA anti-KLH and S-IgA anti-CT responses in the intestinal secretions of individual mice. Similarly, in the lps congenic strains, mice of the endotoxinresponsive strain that were fed both CT and KLH had substantially higher S-IgA and plasma IgG responses to KLH than did mice of the endotoxin-unresponsive strain. The effect of CT on the induction of oral tolerance to KLH in the H-2 congenic strains was also examined. In contrast to the results above, the abrogation of oral tolerance to KLH by CT occurred in all strains regardless of H-2 haplotype. Similarly, the adjuvant effect of CT on plasma IgG anti-KLH responses after both were given together intraperitoneally was not restricted by H-2. I conclude that the mucosal adjuvanticity of CT is influenced by both the H-2 and Ips genetic loci and that it appears to depend on a vigorous mucosal immune response to CT itself.
glycolipid present on all nucleated cells (6) . CT is a very potent mucosal immunogen, and although the mechanism of its potency remains undefined, both the A and B subunits seem to play a role (25) . One factor involved in the degree of its immunogenicity in mice is the genetic background of the mouse strain. In previous studies, we found different inbred strains of mice vary widely in their immunologic response to CT and that this genetic component could be mapped to the I-A subregion of the major histocompatibility complex (MHC) (10, 14) .
A second unusual property of CT is that of mucosal adjuvanticity; i.e., when a second, unrelated antigen is coadministered with CT into the intestine, a secretory immunoglobulin A (S-IgA) response to the unrelated antigen is generated, even though no such response occurs when the antigen is fed by itself (8, 21) . At the same time, CT abrogates the oral tolerance that otherwise occurs after the feeding of the other, unrelated protein antigen (8) . Again, the mechanism of this adjuvant effect is unclear; however, certain parameters have been defined; e.g., the adjuvant effect is seen only if CT is given with the other antigen by the same route and at the same time (21) .
The present experiments were prompted by the results of some experiments in which there was little or no mucosal adjuvant effect of CT in an inbred strain that was an immunologic low responder to CT itself (unpublished data). These results suggested that there are genetic influences on the mucosal adjuvanticity of CT. In the data reported here, the mucosal adjuvanticity of CT was studied in congenic inbred strains of mice that differ at only a single genetic locus, i.e., H-2 or Ips. The latter locus is of interest because lipopolysaccharide is abundant in the gut, has potent immunologic effects including adjuvant activity (18), and is likely to be present continuously in gut-associated lymphoid tissue, i.e., simultaneously with CT or other antigens given into the intestine.
MATERIALS AND METHODS
Animals. C3H/HeN mice were obtained from Frederick Cancer Research Center, Frederick, Md. All other strains were obtained from the Jackson Laboratory, Bar Harbor, Maine. Most of the mice used were 6-to 12-week-old females.
Schedule of immunization and sampling. CT Collection of samples. Blood was obtained from the retroorbital plexus of ether-anesthetized mice by using heparinized capillary tubes. After transfer to small plastic centrifuge tubes and centrifugation for 5 min at 11,000 x g in a microcentrifuge, the plasma was aspirated off and stored at -20°C until assay. Intestinal secretions were collected by using a lavage technique which has been described (11).
CT AS A MUCOSAL ADJUVANT 2875 Briefly, the mice were placed on a square (12 by 12 cm) of galvanized wire mesh which was in turn placed on a plastic petri dish (100 by 15 mm) containing 3 ml of a solution of protease inhibitors. The mice were kept on the wire mesh by inverting a 600-ml glass beaker over the mice. Four doses of 0.5 ml of the lavage solution were given i.g. at 15-min intervals by using a blunt-tipped feeding needle. The lavage solution consisted of 25 mM NaCl, 40 mM Na2SO4, 10 mM KC1, 20 mM NaHCO3, and 48.5 mM polyethylene glycol (average molecular weight = 3,350). Thirty minutes after the last doses of the lavage solution, the mice were given 0. 
RESULTS
Effect of H-2 MHC locus on mucosal adjuvanticity of CT. Two sets of H-2 congenic mice were used in these experiments, the first set being B10 (H-2") and B10.BR (H-2k) and the second set being C3H.SW (H-2b') and C3H/HeN (H-2k).
Groups of five mice each were given saline, 10 jLg of CT, 5 mg of KLH, or both KLH and CT i.g. The antibody levels that were present in intestinal lavage and plasma are shown in Tables 1 and 2 , respectively. The intestinal S-IgA responses to CT varied among the congenic inbred strains as had been previously reported, being high in H-2b strains and low in H-?2 strains regardless of the other genes of the background strain (Table 1) . Again, as previously reported, the feeding of KLH alone did not result in an intestinal or plasma antibody response to this protein. Importantly, in the groups fed both KLH and CT, the intestinal S-IgA anti-KLH response was enhanced by CT only in the H-2b strains (BlO and C3H.SW), whereas in the H-2k strains (B1O.BR and C3H/HeN) there was little or no adjuvant effect of CT evident ( Table 1 ). The plasma IgG responses of the groups fed KLH plus CT showed a similar effect, with plasma IgG anti-KLH being markedly enhanced in the B10 strain but not in B1O.BR (Table 2 ). Both C3H strains had weak plasma IgG responses to KLH, but the increase over background in C3H.SW (H-2b) was slightly greater than that in C3H/HeN (H-y2).
Intestinal samples from individual mice of the different H-2 congenic strains were separately identified. Figure 1 shows the S-IgA anti-KLH plotted against S-IgA anti-CT present in the day 21 (Tables 1 and 4) (8, 9) . A striking exception to this pattern of response is manifested by CT, which both stimulates a strong mucosal S-IgA response and does not generate oral tolerance when fed to mice (8, 9) . The immune responses of the groups of mice fed KLH alone and fed CT alone in the present study are very similar to the results that were obtained in previous reports. They were included in this study as controls against which to compare the results obtained when both KLH and CT were fed together to mice of congenic strains that differ at only a single genetic locus.
In previous studies, we reported that coadministration of KLH and CT into the intestines of mice dramatically altered the pattern of response to KLH by abrogating oral tolerance and stimulating an intestinal S-IgA anti-KLH response (8) . This observation has been repeated now for multiple antigen systems (1, 19, 21) , and the use of CT as a mucosal adjuvant is emerging as an important strategy for mucosal immunization and oral vaccine development (7) . There are a number of variables that have been defined and need to be considered in such usage of CT as discussed below. Whether genetic factors influence CT's adjuvanticity has been previously examined in two previous studies. One study found variable but quantitative differences in several H-2 disparate inbred strains of mice, but the interpretation was clouded by differences in multiple background genes among the strains (32) . The second found no evidence of H-2 restriction of adjuvanticity of CT-B when it was coadministered in high concentrations, along with influenza virus hemagglutinin, into the nose (16) . The present study used congenic inbred strains of mice, focusing on two well-defined genetic loci, H-2 and Ips. The key finding is that the mucosal adjuvanticity of CT was notably influenced by each of these genetic loci: mice that were of the H-2b haplotype and that were Ips responsive exhibited a much more pronounced mucosal adjuvant effect of CT. In addition, in mice of different H-2 haplotypes, the intestinal S-IgA anti-CT and S-IgA anti-KLH responses of individual mice showed a strong positive correlation, indicating that the adjuvanticity of CT is related to its immunogenicity. This finding may have significant implications for the use of CT as a mucosal adjuvant in (17, 26) . This relationship between the immunogenicity and adjuvanticity of CT may limit its effectiveness as a mucosal adjuvant in previously immunized individuals, but this theory needs to be directly examined.
The genetic background of the individual can now be added to the important parameters that define the mucosal adjuvanticity of CT. Other parameters that have been shown to be important include dose, route, and timing of the CT delivery (21) . Most studies have utilized 1 to 20 ,ug of CT per dose in mice with lesser amounts being relatively ineffective. Both CT and antigen must be given by the same route, i.e., into the intestine, and optimally at the same time. Delivery of CT hours apart from the antigen is ineffective (21) . This relatively small window of adjuvanticity may explain why CIT administration does not cause a general increase in S-IgA levels or the development of S-IgA antibodies to common (24) . These parameters do indicate that adjuvanticity is due to a transient action on the local mucosa, presumably by effects in the lymphoid follicles of gut-associated lymphoid tissue; however, the exact site of its adjuvant effect has yet to be experimentally demonstrated.
The genetic effects on CT's mucosal adjuvanticity for S-IgA responses in the present study contrast with the lack of either genetic locus to affect the ability of CT to abrogate oral tolerance or to act as a parenteral immunogen. However, both of the latter results may reflect quantitative rather than qualitative differences from its mucosal effects. Oral tolerance has been shown to involve the generation of CD8+ suppressor T cells (28) . It is quite possible that the inhibition of this T-cell subset might be very sensitive to the effects of CT. Indeed, in in vitro studies we have found that both CT and CT-B subunit are potent inhibitors of T-cell activation and that the CD8+ T-cell subset is more susceptible to this inhibition than is the CD4+ T-cell subset (13) . These in vitro studies also fail to show any effects of the H-2 locus on such inhibition, but whether these observations relate to the present findings is unclear. The lack of genetic effect on the parenteral adjuvanticity of CT might be interpreted as indicating that the mucosal and parenteral adjuvant effects involve different mechanisms. However, some genetic restrictions can be overcome by high doses of antigen and the groups receiving parenteral KLH plus CT very likely received a great deal more of both KLH and CT than are delivered to mucosal lymphoid tissues after i.g. feeding,
given the anticipated degradation of these proteins in the gut by acid, proteases, and bile; thus, a genetic restriction might have been evident at more limited doses of adjuvant and antigen. This point may relate also to the discordance of the present results with those of Hirabayashi et al., who gave high concentrations of CT-B as an adjuvant into the nose (16) . The effective dose by this route was also likely much higher than when the same amounts are given i.g. The lack of an H-2 restriction when the nasal route was used may thus correspond to the lack of H-2 restriction after parenteral administration in the present studies. If so, this implies that the H-2 restriction with the mucosal route might be overcome by greater amounts of CT.
The mechanism of CT's mucosal adjuvanticity is likely to be complex and multifactorial. A number of possibilities have been proposed, including an increase in antigen-presenting cell function in the mucosa (4, 20) and an enhanced switching of IgCH genes to favor both IgG and IgA (23) .
Interestingly, the systems that have demonstrated these effects have utilized lipopolysaccharide as a cofactor to stimulate cells in vitro. The observation here that the Ips locus is an important determinant of CT's adjuvanticity supports these potential mechanisms. A third mechanism that has been proposed is that of an increased permeability of the intestinal mucosa, presumably allowing antigen to penetrate (22) . This mechanism might also show evidence of H-2 restriction in that GM, ganglioside expression (15, 30) and the intestinal fluid accumulation after CT administration (27) 
